Inventor · disambiguated record
Per-Göran Gillberg
Also filed as: GILLBERG PER-GOERAN · GILLBERG PER-GORAN · GILLBERG PER-GÖRAN
54 granted patents·20 pending applications·755 citations·filing 2001–2025
99Inventor score
Top patents by PatentIndex Score
74 records- 0199US11572350B1Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Feb 7, 2023·17 cites·15 claims
- 0299US11267794B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Mar 8, 2022·21 cites·16 claims
- 0399US11180465B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Nov 23, 2021·25 cites·18 claims
- 0499US11111224B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Sep 7, 2021·30 cites·10 claims
- 0599US11014898B1Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted May 25, 2021·30 cites·25 claims
- 0698US12134606B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Nov 5, 2024·5 cites·19 claims
- 0798US11891368B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Feb 6, 2024·10 cites·17 claims
- 0898US11773071B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Oct 3, 2023·14 cites·15 claims
- 0998US11732006B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2021·Granted Aug 22, 2023·11 cites·10 claims
- 1098US11708340B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 25, 2023·12 cites·17 claims
- 1198US11377429B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 5, 2022·13 cites·5 claims
- 1298US11306064B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Apr 19, 2022·17 cites·21 claims
- 1398US11225466B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jan 18, 2022·23 cites·20 claims
- 1498US10981952B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2020·Granted Apr 20, 2021·20 cites·12 claims
- 1598US10975045B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Apr 13, 2021·23 cites·9 claims
- 1698US10941127B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Mar 9, 2021·28 cites·14 claims
- 1798US10487111B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2018·Granted Nov 26, 2019·23 cites·10 claims
- 1898US10093697B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Oct 9, 2018·25 cites·8 claims
- 1998US10011633B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Jul 3, 2018·20 cites·7 claims
- 2098US10000528B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Jun 19, 2018·18 cites·8 claims
- 2198US9694018B1IBAT inhibitors for the treatment of liver diseaseALBIREO AB·Filed 2016·Granted Jul 4, 2017·47 cites·15 claims
- 2298US9688720B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2016·Granted Jun 27, 2017·27 cites·6 claims
- 2397US12202809B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Jan 21, 2025·4 cites·17 claims
- 2497US12187812B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2022·Granted Jan 7, 2025·3 cites·10 claims
- 2597US11603359B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Mar 14, 2023·11 cites·18 claims
- 2697US10975046B2Crystal modifications of odevixibatALBIREO AB·Filed 2019·Granted Apr 13, 2021·22 cites·20 claims
- 2797US10793534B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2019·Granted Oct 6, 2020·21 cites·10 claims
- 2897US10221212B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2018·Granted Mar 5, 2019·11 cites·8 claims
- 2996US12060338B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Aug 13, 2024·5 cites·15 claims
- 3096US12024495B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 2, 2024·5 cites·10 claims
- 3196US11801226B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2020·Granted Oct 31, 2023·11 cites·15 claims
- 3296US11583539B2Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitorsALBIREO AB·Filed 2021·Granted Feb 21, 2023·13 cites·29 claims
- 3396US11365182B2Crystal modifications of odevixibatALBIREO AB·Filed 2020·Granted Jun 21, 2022·10 cites·18 claims
- 3496US11261212B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2016·Granted Mar 1, 2022·17 cites·8 claims
- 3596US10786529B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Sep 29, 2020·12 cites·25 claims
- 3695US12187690B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Jan 7, 2025·4 cites·20 claims
- 3795US12091394B2Crystal modifications of odevixibatALBIREO AB·Filed 2022·Granted Sep 17, 2024·4 cites·27 claims
- 3895US11802115B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2019·Granted Oct 31, 2023·11 cites·16 claims
- 3994US12365658B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Jul 22, 2025·2 cites·16 claims
- 4093US10441605B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·22 claims
- 4193US10441604B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·18 claims
- 4293US2025326789A1Ibat inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2024·Application pending·0 cites
- 4391US11007142B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted May 18, 2021·5 cites·21 claims
- 4491US10610543B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2018·Granted Apr 7, 2020·4 cites·19 claims
- 4590US7514421B2Use of an IBAT inhibitor for the treatment of constipationALBIREO AB·Filed 2004·Granted Apr 7, 2009·92 cites·4 claims
- 4688US10864228B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Dec 15, 2020·2 cites·30 claims
- 4788US10799527B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Oct 13, 2020·2 cites·30 claims
- 4886US10881685B2Cholestyramine granules, oral cholestyramine formulations and use thereofALBIREO AB·Filed 2018·Granted Jan 5, 2021·2 cites·27 claims
- 4986US2025387449A1Pharmaceutical combination comprising an ibat inhibitor and a bile acid binderALBIREO AB·Filed 2025·Application pending·0 cites
- 5085US2025019354A1Crystal Modifications of OdevixibatALBIREO AB·Filed 2024·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Per-Göran Gillberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →